To determine whether patients with MBM would likely benefit from immunotherapy, we assessed the immunogenicity of MBM at the transcriptomic level by calculating the interferon-gamma (IFNγ)24 score and the T cell-inflamed signature score for each tumor sample in our melanoma cohort25. This evidence concerns the gene IFNG and melanoma.